Reflexology pressing on certain parts of the foot to produce an effect elsewhere in the body." The Australian Government's Department of Health define reflexology as "a system of applying pressure, usually to the feet, which practitioners believe stimulates energy and releases 'blockages' in specific areas that cause pain or illness." In 2015 the Australian Government's Department of Health published the results of a review of alternative therapies that sought to determine if any were suitable for being covered by health insurance; reflexology was one of 17 therapies evaluated for which no clear evidence of effectiveness was found. Accordingly In 2017 the
Antisense therapy respectively. Starting in 2004, researchers in the US have been conducting research on using antisense technology to combat HIV. In February 2010 researchers reported success in reducing HIV viral load using patient T-cells which had been harvested, modified with an RNA antisense strand to the HIV viral envelope protein, and re-infused into the patient during a planned lapse in retroviral drug therapy. In 2004, development of an antisense therapy for spinal muscular atrophy was started. Over the following years, an antisense oligonucleotide later named nusinersen was developed by Ionis Pharmaceuticals under a licensing agreement with Biogen. In December 2016, nusinersen